Buy Ocugen For Imminent Catalysts
Photo by MarsBars/E+ via Getty Images
Ocugen (OCGN) burst into a mid-cap ($1.87 billion) biotech when it finalized its late entry into the COVID-19 vaccine race in February. Investors should buy as soon as possible before the company submits an Emergency Use Authorization (EUA) for COVAXIN to the U.S. Food and Drug Administration (FDA), then ride the anticipated run-up until the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting shortly thereafter. The day before…
